Michael Thomas Henderson insider trades

Open-market stock purchases and sales by Michael Thomas Henderson, Chief Executive Officer at Apogee Therapeutics, Inc, from SEC Form 4 filings since Jul 1, 2019.

Track record: 100% of 1 scored buy are up 5% or more since purchase, averaging +298%.

Recent trades

DateStockTradeValue
Jun 22, 2026APGE Apogee Therapeutics, IncSold$10.6M
Jun 22, 2026SYRE Spyre Therapeutics, IncSold$2M
Jun 10, 2026APGE Apogee Therapeutics, IncSold$557K
Jun 10, 2026APGE Apogee Therapeutics, IncSold$634K
Jun 10, 2026APGE Apogee Therapeutics, IncSold$90.9K
Jun 10, 2026APGE Apogee Therapeutics, IncSold$134K
Jun 10, 2026APGE Apogee Therapeutics, IncSold$199K
Jun 10, 2026APGE Apogee Therapeutics, IncSold$53.4K
May 27, 2026SYRE Spyre Therapeutics, IncBought (not open market)—
May 13, 2026APGE Apogee Therapeutics, IncSold$1.5M
May 13, 2026APGE Apogee Therapeutics, IncSold$111K
May 8, 2026SYRE Spyre Therapeutics, IncSold$174K
May 8, 2026SYRE Spyre Therapeutics, IncSold$2.5M
May 8, 2026SYRE Spyre Therapeutics, IncSold$1.9M
May 8, 2026SYRE Spyre Therapeutics, IncSold$1.5M
Apr 16, 2026APGE Apogee Therapeutics, IncBought (not open market)—
Apr 8, 2026APGE Apogee Therapeutics, IncSold$1.5M
Apr 8, 2026APGE Apogee Therapeutics, IncSold$167K
Apr 8, 2026APGE Apogee Therapeutics, IncSold$17K
Mar 11, 2026APGE Apogee Therapeutics, IncSold$621K
Mar 11, 2026APGE Apogee Therapeutics, IncSold$615K
Mar 11, 2026APGE Apogee Therapeutics, IncSold$259K
Feb 11, 2026APGE Apogee Therapeutics, IncSold$724K
Feb 11, 2026APGE Apogee Therapeutics, IncSold$481K
Feb 11, 2026APGE Apogee Therapeutics, IncSold$62.1K

Companies traded

  • APGE Apogee Therapeutics, Inc: 49 sales, last Jun 22, 2026
  • SYRE Spyre Therapeutics, Inc: 5 sales, last Jun 22, 2026
  • ARYD ARYA Sciences Acquisition Corp IV: other filings, last Jul 31, 2024
  • BBIO BridgeBio Pharma, Inc: 1 buy, 35 sales, last Dec 15, 2020

Get free alerts when Michael Thomas Henderson files a new trade →